-
3
-
-
39149104690
-
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
-
Korn EL,Liu PY,Lee SJ, et al.Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.J Clin Oncol. 2008;26:527-534.
-
(2008)
J Clin Oncol
, vol.26
, pp. 527-534
-
-
Korn, E.L.1
Liu, P.Y.2
Lee, S.J.3
-
4
-
-
79951928689
-
Novel mitogen-activated protein kinase inhibitors
-
Chapman MS,Miner JN.Novel mitogen-activated protein kinase inhibitors.Expert Opin Investig Drugs. 2011;20:209-220.
-
(2011)
Expert Opin Investig Drugs
, vol.20
, pp. 209-220
-
-
Chapman, M.S.1
Miner, J.N.2
-
5
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
Davies H,Bignell GR,Cox C, et al.Mutations of the BRAF gene in human cancer.Nature. 2002;417:949-954.
-
(2002)
Nature
, vol.417
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
-
6
-
-
84864722943
-
NRAS mutation status is an independent prognostic factor in metastatic melanoma
-
Jakob JA,Bassett RL,Ng CS, et al.NRAS mutation status is an independent prognostic factor in metastatic melanoma.Cancer. 2012;118:4014-4023.
-
(2012)
Cancer
, vol.118
, pp. 4014-4023
-
-
Jakob, J.A.1
Bassett, R.L.2
Ng, C.S.3
-
7
-
-
84978034236
-
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
-
Long GV,Menzies AM,Nagrial AM, et al.Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.J Clin Oncol. 2011;29:1239-1246.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1239-1246
-
-
Long, G.V.1
Menzies, A.M.2
Nagrial, A.M.3
-
8
-
-
65549130220
-
Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions
-
Klein RM,Aplin AE.Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions.Cancer Res. 2009;69:2224-2233.
-
(2009)
Cancer Res
, vol.69
, pp. 2224-2233
-
-
Klein, R.M.1
Aplin, A.E.2
-
9
-
-
78651457445
-
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A
-
Arozarena I,Sanchez-Laorden B,Packer L, et al.Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.Cancer Cell. 2011;19:45-57.
-
(2011)
Cancer Cell
, vol.19
, pp. 45-57
-
-
Arozarena, I.1
Sanchez-Laorden, B.2
Packer, L.3
-
10
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB,Hauschild A,Robert C, et al.Improved survival with vemurafenib in melanoma with BRAF V600E mutation.N Engl J Med. 2011;364:2507-2516.
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
11
-
-
84865068182
-
Updated overall survival results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib with dacarbazine in previously untreated patients with BRAFV600E-mutated melanoma
-
Chapman PB,Hauschild A,Robert C, et al.Updated overall survival results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib with dacarbazine in previously untreated patients with BRAFV600E-mutated melanoma.J Clin Oncol. 2012;30:.
-
(2012)
J Clin Oncol
, vol.30
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
12
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomised controlled trial
-
Hauschild A,Grob JJ,Demidov LV, et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomised controlled trial.Lancet. 2012;380:358-365.
-
(2012)
Lancet
, vol.380
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
-
13
-
-
84882873880
-
An update on BREAK-3, a phase III, randomized trial: dabrafenib versus dacarbazine in patients with BRAF V600E-positive mutation metastatic melanoma
-
Hauschild A,Grob JJ,Demidov LV, et al.An update on BREAK-3, a phase III, randomized trial: dabrafenib versus dacarbazine in patients with BRAF V600E-positive mutation metastatic melanoma.J Clin Oncol. 2013;31:.
-
(2013)
J Clin Oncol
, vol.31
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
-
14
-
-
84898680508
-
-
Tafinlar® (Dabrafenib) US prescribing information2013. Research Triangle Park, NC: GlaxoSmithKline, Accessed July 10
-
Tafinlar® (Dabrafenib) US prescribing information2013. Research Triangle Park, NC: GlaxoSmithKline. http://us.gsk.com/products/assets/us_tafinlar.pdfAccessed July 10, 2013.
-
(2013)
-
-
-
15
-
-
77956513286
-
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
-
Bollag G,Hirth P,Tsai J, et al.Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.Nature. 2010;467:596-599.
-
(2010)
Nature
, vol.467
, pp. 596-599
-
-
Bollag, G.1
Hirth, P.2
Tsai, J.3
-
16
-
-
74849109743
-
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
-
Heidorn SJ,Milagre C,Whittaker S, et al.Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.Cell. 2010;140:209-221.
-
(2010)
Cell
, vol.140
, pp. 209-221
-
-
Heidorn, S.J.1
Milagre, C.2
Whittaker, S.3
-
17
-
-
77949732073
-
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
-
Poulikakos PI,Zhang C,Bollag G,Shokat KM,Rosen N.RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.Nature. 2010;464:427-430.
-
(2010)
Nature
, vol.464
, pp. 427-430
-
-
Poulikakos, P.I.1
Zhang, C.2
Bollag, G.3
Shokat, K.M.4
Rosen, N.5
-
18
-
-
77949685981
-
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
-
Hatzivassiliou G,Song K,Yen I, et al.RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.Nature. 2010;464:431-435.
-
(2010)
Nature
, vol.464
, pp. 431-435
-
-
Hatzivassiliou, G.1
Song, K.2
Yen, I.3
-
19
-
-
84898686165
-
-
Research Triangle Park, NC: GlaxoSmithKline
-
Research Triangle Park, NC: GlaxoSmithKline;.
-
-
-
-
20
-
-
84898680506
-
-
Zelboraf® (Vemurafenib) US prescribing information2013. South San Francisco, CA: Genentech USA, Inc. Accessed July 10
-
Zelboraf® (Vemurafenib) US prescribing information2013. South San Francisco, CA: Genentech USA, Inc.http://www.gene.com/download/pdf/zelboraf_prescribing.pdf. Accessed July 10, 2013.
-
(2013)
-
-
-
21
-
-
84861083983
-
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumors: a phase 1 dose-escalation trial
-
Falchook GS,Long GV,Kurzrock R, et al.Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumors: a phase 1 dose-escalation trial.Lancet. 2012;379:1893-1901.
-
(2012)
Lancet
, vol.379
, pp. 1893-1901
-
-
Falchook, G.S.1
Long, G.V.2
Kurzrock, R.3
-
22
-
-
84891648456
-
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma
-
Accessed August 20 [published online August5, 2013]
-
AsciertoPAMinorDRibasA. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma [published online August5, 2013]. J Clin Oncol. http://jco.ascopubs.org/content/early/2013/08/05/JCO.2013.49.8691.long. Accessed August 20, 2013.
-
(2013)
J Clin Oncol
-
-
Ascierto, P.A.1
Minor, D.2
Ribas, A.3
-
23
-
-
84868120907
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
-
Long GV,Trefzer U,Davies MA, et al.Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.Lancet Oncol. 2012;13:1087-1095.
-
(2012)
Lancet Oncol
, vol.13
, pp. 1087-1095
-
-
Long, G.V.1
Trefzer, U.2
Davies, M.A.3
-
24
-
-
79953781233
-
Prognostic factors for survival in melanoma patients with brain metastases
-
Davies MA,Liu P,McIntyre S, et al.Prognostic factors for survival in melanoma patients with brain metastases.Cancer. 2011;117:1687-1696.
-
(2011)
Cancer
, vol.117
, pp. 1687-1696
-
-
Davies, M.A.1
Liu, P.2
McIntyre, S.3
-
25
-
-
2142644507
-
Determinants of outcome in melanoma patients with cerebral metastases
-
Fife KM,Coleman MH,Stevens GN, et al.Determinants of outcome in melanoma patients with cerebral metastases.J Clin Oncol. 2004;22:1293-1300.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1293-1300
-
-
Fife, K.M.1
Coleman, M.H.2
Stevens, G.N.3
-
26
-
-
44849122610
-
Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features
-
Raizer JJ,Hwu WJ,Pangeas KS, et al.Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features.Neuro Oncol. 2008;10:199-207.
-
(2008)
Neuro Oncol
, vol.10
, pp. 199-207
-
-
Raizer, J.J.1
Hwu, W.J.2
Pangeas, K.S.3
-
27
-
-
0031975369
-
Demographics, prognosis, and the therapy in 702 patients with brain metastases from malignant melanoma
-
Sampson JH,Carter JH,Friedman AH,Seigler HF.Demographics, prognosis, and the therapy in 702 patients with brain metastases from malignant melanoma.J Neurosurg. 1998;88:11-20.
-
(1998)
J Neurosurg
, vol.88
, pp. 11-20
-
-
Sampson, J.H.1
Carter, J.H.2
Friedman, A.H.3
Seigler, H.F.4
-
28
-
-
84871900504
-
Melanoma brain metastases and vemurafenib: need for further investigation
-
Rochet NM,Dronca RS,Kottschade LA, et al.Melanoma brain metastases and vemurafenib: need for further investigation.Mayo Clin Proc. 2012;87:976-981.
-
(2012)
Mayo Clin Proc
, vol.87
, pp. 976-981
-
-
Rochet, N.M.1
Dronca, R.S.2
Kottschade, L.A.3
-
29
-
-
84858752302
-
An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases
-
Dummer R,Rinderknecht J,Goldinger SM, et al.An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.J Clin Oncol. 2011;29:.
-
(2011)
J Clin Oncol
, vol.29
-
-
Dummer, R.1
Rinderknecht, J.2
Goldinger, S.M.3
-
30
-
-
84873728334
-
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
-
Das Thakur M,Salangsang F,Landman AS, et al.Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.Nature. 2013;494:251-255.
-
(2013)
Nature
, vol.494
, pp. 251-255
-
-
Das Thakur, M.1
Salangsang, F.2
Landman, A.S.3
-
31
-
-
84869499716
-
Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor
-
Seghers AC,Wilgenhof S,Lebbé C,Neyns B.Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.Melanoma Res. 2012;22:466-472.
-
(2012)
Melanoma Res
, vol.22
, pp. 466-472
-
-
Seghers, A.C.1
Wilgenhof, S.2
Lebbé, C.3
Neyns, B.4
-
32
-
-
84872857932
-
Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management
-
Manousaridis I,Mavridou S,Goerdt S,Leverkus M,Utikal J.Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.J Eur Acad Dermatol Venereol. 2013;27:11-18.
-
(2013)
J Eur Acad Dermatol Venereol
, vol.27
, pp. 11-18
-
-
Manousaridis, I.1
Mavridou, S.2
Goerdt, S.3
Leverkus, M.4
Utikal, J.5
-
34
-
-
84875453915
-
Analysis of dermatologic events in vemurafenib-treated patients with melanoma
-
Lacouture ME,Duvic M,Hauschild A, et al.Analysis of dermatologic events in vemurafenib-treated patients with melanoma.Oncologist. 2013;18:314-322.
-
(2013)
Oncologist
, vol.18
, pp. 314-322
-
-
Lacouture, M.E.1
Duvic, M.2
Hauschild, A.3
-
35
-
-
84868193136
-
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
-
Anforth RM,Blumetti TC,Kefford RF, et al.Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.Br J Dermatol. 2012;167:1153-1160.
-
(2012)
Br J Dermatol
, vol.167
, pp. 1153-1160
-
-
Anforth, R.M.1
Blumetti, T.C.2
Kefford, R.F.3
-
36
-
-
84862908097
-
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
-
Su F,Viros A,Milagre C, et al.RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.N Engl J Med. 2012;366:207-215.
-
(2012)
N Engl J Med
, vol.366
, pp. 207-215
-
-
Su, F.1
Viros, A.2
Milagre, C.3
-
37
-
-
84863116743
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
-
Sosman JA,Kim KB,Schuter L, et al.Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.N Engl J Med. 2012;366:707-714.
-
(2012)
N Engl J Med
, vol.366
, pp. 707-714
-
-
Sosman, J.A.1
Kim, K.B.2
Schuter, L.3
-
38
-
-
84872361487
-
Dabrafenib and its potential for the treatment of metastatic melanoma
-
Menzies AM,Long GV,Murali R.Dabrafenib and its potential for the treatment of metastatic melanoma.Drug Des Devel Ther. 2012;6:391-405.
-
(2012)
Drug Des Devel Ther
, vol.6
, pp. 391-405
-
-
Menzies, A.M.1
Long, G.V.2
Murali, R.3
-
39
-
-
84857012981
-
Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities
-
Lemech C,Arkenau HT.Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities.Clin Med Insights Oncol. 2012;6:53-66.
-
(2012)
Clin Med Insights Oncol
, vol.6
, pp. 53-66
-
-
Lemech, C.1
Arkenau, H.T.2
-
40
-
-
84875785905
-
Hepatotoxicity with combination of vemurafenib and ipilimumab
-
Ribas A,Hodi FS,Callahan M,Konto C,Wolchok J.Hepatotoxicity with combination of vemurafenib and ipilimumab.N Engl J Med. 2013;368:1365-1366.
-
(2013)
N Engl J Med
, vol.368
, pp. 1365-1366
-
-
Ribas, A.1
Hodi, F.S.2
Callahan, M.3
Konto, C.4
Wolchok, J.5
-
41
-
-
84873823736
-
BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety
-
Noor R,Trinh VA,Kim KB,Hwu WJ.BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety.Clin Invest. 2011;1:1127-1139.
-
(2011)
Clin Invest
, vol.1
, pp. 1127-1139
-
-
Noor, R.1
Trinh, V.A.2
Kim, K.B.3
Hwu, W.J.4
-
42
-
-
84873819555
-
Which drug, and when, for patients with BRAF-mutant melanoma?
-
Jang S,Atkins MB.Which drug, and when, for patients with BRAF-mutant melanoma?.Lancet Oncol. 2013;14:e60-e69.
-
(2013)
Lancet Oncol
, vol.14
-
-
Jang, S.1
Atkins, M.B.2
-
43
-
-
84875706825
-
Resistance to BRAF-targeted therapy in melanoma
-
Sullivan RJ,Flaherty KT.Resistance to BRAF-targeted therapy in melanoma.Eur J Cancer. 2013;49:1297-1304.
-
(2013)
Eur J Cancer
, vol.49
, pp. 1297-1304
-
-
Sullivan, R.J.1
Flaherty, K.T.2
-
44
-
-
84868224906
-
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
-
Flaherty KT,Infante JR,Daud A, et al.Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.N Engl J Med. 2012;367:1694-1703.
-
(2012)
N Engl J Med
, vol.367
, pp. 1694-1703
-
-
Flaherty, K.T.1
Infante, J.R.2
Daud, A.3
-
45
-
-
84898677747
-
-
National Comprehensive Cancer Network. NCCN Guidelines: melanoma, version 1.2014. Accessed August 20
-
National Comprehensive Cancer Network. NCCN Guidelines: melanoma, version 1.2014. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Accessed August 20, 2013.
-
(2013)
-
-
|